Skip to main content
SPRY
NASDAQ Life Sciences

ARS Pharma 10-Q: Q3 Revenue $37.7M, Net Loss Narrows to $35.6M, $138.4M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.65
Mkt Cap
$263.535M
52W Low
$2.59
52W High
$13.15
52W Position info
2.3% above low
Off High info
80% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

SPRY is trading near its 52-week low of $2.59 (2.3% above the low).

Summary

ARS Pharma's Q3 10-Q shows revenue of $37.7M and a narrowed $35.6M net loss on sharply lower SG&A, with $138.4M in cash and investments and $125.0M of term debt outstanding.


Key Events · Earnings and Guidance · SPRY

  • Q3 Revenue $37.7M, Loss Narrows

    Total revenue rose to $37.7M from $32.5M, including $33.4M of U.S. neffy product revenue; net loss fell to $35.6M, or $(0.36) per share, from $51.2M, or $(0.52).

  • SG&A Cut to $43.5M

    Selling, general and administrative expense dropped to $43.5M from $74.8M a year ago, a $31.2M reduction driven mainly by $38.0M less marketing spend.

  • Cash $138.4M, Debt $125.0M

    Cash, cash equivalents and short-term investments were $138.4M at September 30, 2026; gross term loans reached $125.0M after the $25.0M Term B draw on September 25, 2026.

  • Equity Turns to Deficit

    Total stockholders' equity went from $114.258M at December 31, 2025 to a $(11.955)M deficit, with the accumulated deficit at $453.1M.


Analysis · SPRY · Life Sciences

The headline numbers were already out via the morning 8-K, but the 10-Q is where the balance sheet and the risks live. Revenue of $37.7M against $32.5M a year ago came with SG&A cut to $43.5M from $74.8M, so the quarterly net loss fell to $35.6M from $51.2M — the cost side of the breakeven-by-end-2027 story is actually moving. Against that, stockholders' equity has flipped to a $(11.955)M deficit, the company has drawn $125.0M of term debt at a rate of 5.50% plus SOFR (floored at 3.00%), and it expensed a $12.5M upfront license payment in the quarter. Cash of $138.4M is the runway number that matters. The legal file also thickened: a securities class action filed August 5, 2026 over the neffy insurance-coverage timeline, a TCPA fax class action, and Lupin's October 1, 2026 stipulation that its proposed generics meet six asserted patents — leaving validity as the fight.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SPRY was trading at $2.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $263.5M. The 52-week trading range was $2.59 to $13.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SPRY - Latest Insights

SPRY
Nov 05, 2026, 4:04 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $2.81 info
Change: +$0.160 (+6%) info
Market Cap: $280.474M info
SPRY
Nov 05, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $2.81 info
Change: +$0.160 (+6%) info
Market Cap: $280.474M info
SPRY
Aug 13, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.31
Real-time Price: $2.81 info
Change: -$2.50 (-47%) info
Market Cap: $280.474M info
SPRY
Aug 13, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $2.81 info
Change: -$2.51 (-47%) info
Market Cap: $280.474M info
SPRY
Aug 13, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $2.81 info
Change: -$2.31 (-45%) info
Market Cap: $280.474M info